Clinical trial • Phase I • Infectious Disease

PBGENE-HBV for Chronic hepatitis B

Phase I trial of PBGENE-HBV for Chronic hepatitis B. adaptive. 22 participants.

Overview

Trial Therapeutic Area
Infectious Disease
Trial Disease
Chronic hepatitis B
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
26-11-2025
First CTIS Authorization Date
08-04-2026

Trial design

adaptive Phase I trial across 3 sites in France, Romania.

Adaptive
True, Dose-escalation: study will use increasing dose amounts to assess safety and tolerability (as described in the public title).
Single Multiple Or Escalation Dose Combined
Yes
Target Sample Size
22

Recruitment

Planned Sample Size
22
Recruitment Window Months
21

Geography

Total Number Of Sites
3
Total Number Of Participants
20

France

Earliest CTIS Part Ii Submission Date
23-03-2026
Latest Decision Or Authorization Date
08-04-2026
Processing Time Days
16
Number Of Sites
1
Number Of Participants
3

Sites

Site Name
Hopital Beaujon
Department Name
Hepatology
Principal Investigator Name
Tarik Asselah
Principal Investigator Email
tarik.asselah@aphp.fr
Contact Person Name
Tarik Asselah
Contact Person Email
tarik.asselah@aphp.fr

Romania

Earliest CTIS Part Ii Submission Date
09-03-2026
Latest Decision Or Authorization Date
14-04-2026
Processing Time Days
36
Number Of Sites
2
Number Of Participants
17

Sites

Site Name
County Clinical Emergency Hospital Cluj-Napoca
Department Name
Medical
Principal Investigator Name
Vlad Ichim
Principal Investigator Email
Vlad.ichim.ext@arensia-em.com
Contact Person Name
Vlad Ichim
Contact Person Email
Vlad.ichim.ext@arensia-em.com
Site Name
National Institute of Infectious Diseases Prof. Dr. Matei Bal
Department Name
Infectious Diseases
Principal Investigator Name
Anca Streinu-Cercel
Principal Investigator Email
anca.streinucercel@gmail.com
Contact Person Name
Anca Streinu-Cercel
Contact Person Email
anca.streinucercel@gmail.com

Sponsor

Primary sponsor

Full Name
Precision Biosciences Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
PBGENE-HBV
First In Human
Yes

Related trials

Other published trials that may interest you.